跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41,166 条关于
“Savara Inc”
全部
41,166
临床试验
11,393
药物
1,625
机构
6,199
资讯
21,949
去年
Savara Announces Presentation of Phase 3 IMPALA-2 Trial Results for Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
去年
Savara to Present Phase 3 IMPALA-2 Trial Data on Molgramostim for Rare Lung Disease at Multiple International Conferences
去年
Savara's Molgramostim Shows Promise in Autoimmune Pulmonary Alveolar Proteinosis
去年
Savara's Molgramostim Shows Promise in Autoimmune Pulmonary Alveolar Proteinosis
去年
Savara Reports 50% Increase in Autoimmune PAP Patient Population, Plans December 2025 FDA Resubmission for MOLBREEVI
去年
Savara Launches Expanded Access Program for Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
去年
Savara Plans Rolling Submission to FDA for MOLBREEVI in Autoimmune Pulmonary Alveolar Proteinosis
去年
Savara Initiates FDA Submission for MOLBREEVI in Rare Lung Disease
12个月前
Savara Receives FDA Alignment on MOLBREEVI BLA Resubmission, Stock Surges 15.76% Following Strategic Financing
去年
Savara to Present Phase 3 IMPALA-2 Trial Data and Host aPAP Symposium at ERS Congress 2025
第 1 页,共 2195 页
上一页
下一页